▁British 8.5859375
▁Bi 8.0390625
ote 1.8125
ch 0.12213134765625
’ 4.39453125
s 0.00771331787109375
▁Mar 8.1875
im 7.85546875
ast 0.8603515625
at 0.00034499168395996094
▁anti 8.7421875
- 0.051788330078125
can 1.4638671875
cer 0.0009207725524902344
▁treatment 3.07421875
▁will 4.73828125
▁be 0.74658203125
▁review 4.9921875
ed 0.002323150634765625
▁at 3.892578125
▁the 1.125
▁up 3.21484375
coming 0.0110626220703125
▁European 2.6875
▁Society 2.1875
▁for 0.4501953125
▁Medical 0.07757568359375
▁On 0.003337860107421875
col 0.002613067626953125
ogy 5.9723854064941406e-05
▁( 0.29052734375
ES 0.006771087646484375
MO 0.00010907649993896484
) 0.03448486328125
▁conference 2.1484375
▁in 0.9541015625
▁Vienna 2.720703125
. 1.146484375
▁The 1.794921875
▁top 8.578125
ical 2.44921875
▁gel 1.8369140625
- 4.203125
based 0.384521484375
▁treatment 1.0205078125
, 2.26171875
▁originally 5.01171875
▁developed 0.39111328125
▁to 2.951171875
▁treat 0.474609375
▁breast 5.90625
▁cancer 0.1357421875
, 0.2076416015625
▁has 1.3857421875
▁shown 1.7216796875
▁prom 1.998046875
ising 0.0030345916748046875
▁results 0.2958984375
▁in 0.32958984375
▁clin 3.12890625
ical 0.0020618438720703125
▁tri 0.151611328125
als 9.930133819580078e-05
. 2.771484375
<0x0A> 0.6953125
Mar 1.17578125
im 0.014190673828125
ast 0.0006165504455566406
at 0.00034427642822265625
▁is 0.76708984375
▁a 0.95166015625
▁matrix 3.865234375
▁metal 0.0288543701171875
lo 0.0012807846069335938
prote 0.06756591796875
in 0.0631103515625
ase 0.018218994140625
▁in 1.1923828125
hib 0.0004367828369140625
itor 0.004764556884765625
, 1.28515625
▁which 0.93115234375
▁means 2.392578125
▁it 0.338623046875
▁targets 3.234375
▁en 2.19921875
zym 0.00012624263763427734
es 0.01392364501953125
▁that 0.5498046875
▁play 2.802734375
▁a 0.296142578125
▁role 0.736328125
▁in 0.004840850830078125
▁the 1.267578125
▁growth 1.5400390625
▁and 0.62353515625
▁spread 0.18017578125
▁of 0.020355224609375
▁cancer 0.3466796875
▁cells 0.77197265625
. 0.1351318359375
▁In 2.490234375
▁pre 3.1796875
cl 0.69140625
in 6.914138793945312e-05
ical 0.0013141632080078125
▁studies 0.82763671875
, 0.2099609375
▁it 1.7021484375
▁was 1.5810546875
▁shown 0.95556640625
▁to 0.08258056640625
▁in 1.8349609375
hib 0.007656097412109375
it 0.00045680999755859375
▁the 0.8505859375
▁growth 0.451171875
▁of 0.16796875
▁tum 1.7470703125
ors 1.7548828125
▁and 1.65625
▁reduce 1.998046875
▁the 1.134765625
▁ch 5.94140625
ances 0.01462554931640625
▁of 0.048309326171875
▁met 1.3115234375
ast 0.0011568069458007812
asis 0.113525390625
. 0.489501953125
<0x0A> 0.3564453125
The 1.244140625
▁gel 2.431640625
- 1.69921875
based 0.0374755859375
▁form 1.1796875
ulation 0.09454345703125
▁allows 2.919921875
▁the 1.6826171875
▁drug 0.7890625
▁to 0.00335693359375
▁be 0.33056640625
▁applied 1.0068359375
▁top 2.634765625
ically 0.0011577606201171875
▁to 0.93359375
▁the 0.2447509765625
▁breast 3.3359375
▁area 2.814453125
, 0.49560546875
▁which 1.4384765625
▁could 1.9208984375
▁reduce 1.939453125
▁the 0.5048828125
▁side 1.2509765625
▁effects 0.028045654296875
▁associated 0.8583984375
▁with 0.0001748800277709961
▁traditional 1.62109375
▁chem 1.615234375
other 0.0029964447021484375
apy 0.0246734619140625
▁treat 0.72412109375
ments 2.372264862060547e-05
. 0.08343505859375
▁The 2.19140625
▁treatment 1.4267578125
▁is 0.66015625
▁applied 3.66796875
▁using 3.951171875
▁a 0.259521484375
▁patch 3.935546875
, 1.216796875
▁applied 6.40625
▁to 1.533203125
▁the 0.059539794921875
▁breast 1.2353515625
▁area 0.90478515625
▁daily 3.330078125
▁for 0.219970703125
▁two 1.966796875
▁weeks 0.11236572265625
▁prior 6.43359375
▁to 0.00507354736328125
▁surg 0.3330078125
ery 0.017486572265625
. 0.64453125
<0x0A> 0.39306640625
The 1.138671875
▁phase 3.232421875
▁II 1.341796875
▁clin 1.1318359375
ical 0.0003566741943359375
▁trial 0.3017578125
▁conducted 4.0390625
▁on 2.583984375
▁ 0.8857421875
2 1.8291015625
0 1.7041015625
9 3.80078125
▁women 1.51171875
▁with 0.650390625
▁breast 1.2998046875
▁cancer 0.0149383544921875
▁showed 1.0546875
▁a 2.359375
▁significant 1.5888671875
▁improvement 1.1884765625
▁in 0.0223846435546875
▁disease 2.70703125
- 0.11016845703125
free 0.004058837890625
▁surv 0.033111572265625
ival 0.0004665851593017578
▁and 1.7158203125
▁overall 0.64306640625
▁surv 0.0103302001953125
ival 0.0001710653305053711
▁rates 1.31640625
. 1.2021484375
▁After 4.93359375
▁three 2.5078125
▁years 0.0452880859375
, 0.52490234375
▁the 0.7880859375
▁patients 4.78515625
▁who 0.994140625
▁received 0.369873046875
▁Mar 0.60791015625
im 0.00482177734375
ast 0.000530242919921875
at 0.0007381439208984375
▁had 0.302734375
▁a 0.111083984375
▁ 0.284912109375
3 2.044921875
5 2.306640625
% 0.20166015625
▁reduction 1.2939453125
▁in 0.0022258758544921875
▁the 0.43359375
▁risk 0.08740234375
▁of 0.0010900497436523438
▁disease 2.09765625
▁rec 0.484375
urrence 0.00690460205078125
▁compared 1.185546875
▁to 0.033721923828125
▁the 1.5283203125
▁place 1.2275390625
bo 0.00017940998077392578
▁group 0.0163116455078125
. 0.08599853515625
<0x0A> 0.398193359375
The 0.93359375
▁treatment 2.1484375
▁also 2.494140625
▁showed 0.6162109375
▁promise 2.216796875
▁in 0.09771728515625
▁delay 5.890625
ing 0.00015676021575927734
▁the 0.1875
▁pro 1.5341796875
gression 0.0012979507446289062
▁of 0.00684356689453125
▁triple 3.720703125
- 0.21533203125
negative 0.001361846923828125
▁breast 0.022796630859375
▁cancer 0.00894927978515625
, 0.50732421875
▁a 0.70556640625
▁particularly 1.5146484375
▁ag 0.0262298583984375
gress 2.300739288330078e-05
ive 7.152557373046875e-06
▁form 0.250244140625
▁of 0.0023441314697265625
▁the 0.061370849609375
▁disease 0.0025959014892578125
▁with 3.90234375
▁limited 1.0068359375
▁treatment 0.0155181884765625
▁options 0.0001819133758544922
. 0.0244598388671875
▁The 1.9111328125
▁results 2.08984375
▁of 0.3759765625
▁the 0.677734375
▁clin 2.17578125
ical 0.00024962425231933594
▁trial 0.11810302734375
▁were 1.0478515625
▁published 0.57373046875
▁in 0.01355743408203125
▁the 0.13623046875
▁Lanc 3.12890625
et 3.230571746826172e-05
▁On 0.234130859375
col 3.802776336669922e-05
ogy 0.0002429485321044922
▁journal 0.33203125
▁earlier 4.5703125
▁this 0.01224517822265625
▁year 0.041473388671875
. 0.1820068359375
<0x0A> 0.020843505859375
Pro 6.3515625
f 0.1767578125
essor 0.128662109375
▁Jud 5.3828125
ith 0.2005615234375
▁Bl 0.01192474365234375
iss 0.001674652099609375
▁of 3.31640625
▁the 0.39111328125
▁Institute 1.990234375
▁of 0.0312042236328125
▁Can 0.04852294921875
cer 8.07046890258789e-05
▁Research 0.027374267578125
, 0.9345703125
▁one 2.771484375
▁of 0.00042939186096191406
▁the 0.01313018798828125
▁lead 1.6015625
▁investig 1.166015625
ators 0.0009822845458984375
▁of 0.5703125
▁the 0.002178192138671875
▁clin 1.1728515625
ical 0.0002663135528564453
▁trial 0.10443115234375
, 0.028350830078125
▁commented 2.87890625
: 2.37890625
▁" 3.197265625
The 2.046875
▁results 0.98876953125
▁of 0.5673828125
▁this 0.66455078125
▁clin 2.587890625
ical 0.00042176246643066406
▁trial 0.045166015625
▁demonstrate 3.234375
▁the 1.40625
▁potential 0.231201171875
▁of 0.283447265625
▁Mar 1.0234375
im 0.007663726806640625
ast 0.00036597251892089844
at 0.0005288124084472656
▁to 0.625
▁improve 1.5634765625
▁surv 2.2578125
ival 0.00047707557678222656
▁rates 1.93359375
▁for 0.92578125
▁women 0.55810546875
▁with 0.0697021484375
▁breast 0.994140625
▁cancer 0.00211334228515625
. 0.8759765625
▁It 2.865234375
’ 4.48828125
s 0.00020813941955566406
▁exc 2.115234375
iting 0.0001316070556640625
▁to 0.441650390625
▁see 0.36376953125
▁a 1.89453125
▁novel 3.1484375
▁treatment 0.9765625
▁like 2.306640625
▁Mar 1.208984375
im 0.0008869171142578125
ast 9.298324584960938e-05
at 0.00025081634521484375
▁showing 2.728515625
▁such 0.794921875
▁prom 0.8349609375
ising 0.00014829635620117188
▁results 0.09637451171875
." 2.453125
<0x0A> 0.02093505859375
The 1.083984375
▁ES 2.783203125
MO 6.210803985595703e-05
▁conference 0.06988525390625
, 1.6640625
▁which 0.61083984375
▁is 1.759765625
▁being 2.201171875
▁held 0.033447265625
▁from 0.65185546875
▁ 1.7021484375
2 1.3251953125
5 2.712890625
th 1.3515625
▁September 2.373046875
▁to 0.09710693359375
▁ 0.03778076171875
2 0.7470703125
9 0.38037109375
th 0.0008311271667480469
▁September 0.045074462890625
, 0.326171875
▁brings 3.52734375
▁together 0.002460479736328125
▁leading 1.4970703125
▁on 0.85107421875
colog 1.033203125
ists 0.0004563331604003906
▁and 0.92578125
▁medical 3.025390625
▁profession 0.7578125
als 1.5020370483398438e-05
▁to 2.064453125
▁discuss 0.619140625
▁the 0.27197265625
▁latest 0.0015468597412109375
▁develop 0.73583984375
ments 1.0251998901367188e-05
▁in 0.0858154296875
▁cancer 0.406005859375
▁treat 3.455078125
ments 4.1365623474121094e-05
▁and 1.01953125
▁research 0.1922607421875
. 0.005340576171875
<0x0A> 1.1591796875
The 1.2705078125
▁review 4.984375
▁of 0.0902099609375
▁Mar 0.15234375
im 0.0031986236572265625
ast 0.00043272972106933594
at 0.0004355907440185547
▁is 1.302734375
▁expected 1.8544921875
▁to 0.0004367828369140625
▁generate 0.9296875
▁significant 0.39306640625
▁interest 0.0170745849609375
▁among 0.81201171875
▁the 0.880859375
▁health 7.63671875
care 0.037750244140625
▁community 0.400634765625
, 0.44140625
▁with 2.224609375
▁the 0.7734375
▁potential 0.306884765625
▁to 0.5400390625
▁open 5.33203125
▁up 0.181396484375
▁a 1.322265625
▁new 0.021087646484375
▁a 1.1669921875
venue 0.0011606216430664062
▁of 1.408203125
▁treatment 0.1109619140625
▁for 0.0213470458984375
▁breast 0.69140625
▁cancer 0.00366973876953125
▁patients 0.1378173828125
. 0.08477783203125
<0x0A> 0.52587890625
" 4.3515625
Mar 3.083984375
im 0.005069732666015625
ast 0.0001354217529296875
at 0.0003306865692138672
▁has 1.201171875
▁the 0.6123046875
▁potential 0.004566192626953125
▁to 0.0003731250762939453
▁make 3.494140625
▁a 0.0540771484375
▁real 0.99609375
▁difference 0.037261962890625
▁to 1.6181640625
▁the 0.35986328125
▁lives 0.07427978515625
▁of 0.0006794929504394531
▁millions 5.171875
▁of 0.0017633438110351562
▁women 0.61181640625
▁around 1.9150390625
▁the 0.00039649009704589844
▁world 0.0102081298828125
▁who 0.66943359375
▁are 0.056732177734375
▁living 1.861328125
▁with 0.0005803108215332031
▁breast 0.1815185546875
▁cancer 0.0009064674377441406
," 0.5341796875
▁said 0.2578125
▁Dr 1.583984375
. 0.51611328125
▁Tom 5.21484375
▁Brad 6.46484375
sh 0.50048828125
aw 0.01190948486328125
, 0.04327392578125
▁CE 0.7841796875
O 0.00010991096496582031
▁of 0.03509521484375
▁British 0.363037109375
▁Bi 0.01282501220703125
ote 0.000759124755859375
ch 0.0015592575073242188
. 0.2247314453125
▁" 0.2587890625
We 0.29443359375
’ 2.3046875
re 0.0045318603515625
▁thr 2.3359375
illed 1.4066696166992188e-05
▁to 0.1649169921875
▁have 1.123046875
▁the 0.082275390625
▁opportunity 0.0282135009765625
▁to 0.0007314682006835938
▁present 0.529296875
▁our 0.499267578125
▁find 0.67431640625
ings 5.125999450683594e-06
▁at 0.12188720703125
▁the 0.95263671875
▁ES 0.2261962890625
MO 7.176399230957031e-05
▁conference 0.0149688720703125
▁and 0.406494140625
▁look 1.291015625
▁forward 0.0001590251922607422
▁to 0.0001239776611328125
▁discuss 2.0859375
ing 0.00196075439453125
▁the 0.08819580078125
▁potential 0.7919921875
▁of 0.2032470703125
▁Mar 0.771484375
im 0.0007786750793457031
ast 6.282329559326172e-05
at 0.0002675056457519531
▁with 0.1334228515625
▁the 0.6201171875
▁on 2.177734375
col 0.02374267578125
ogy 6.67572021484375e-06
▁community 0.0012636184692382812
." 0.060791015625
<0x0A> 0.168212890625
Bre 4.08984375
ast 0.025543212890625
▁cancer 0.1790771484375
▁is 0.05902099609375
▁the 0.89599609375
▁most 0.062042236328125
▁common 0.07659912109375
▁cancer 1.556640625
▁in 0.52978515625
▁women 0.03857421875
▁world 0.58154296875
wide 0.0001348257064819336
, 0.094970703125
▁with 0.21875
▁approximately 2.990234375
▁ 0.033843994140625
2 0.16943359375
. 0.10601806640625
1 0.67333984375
▁million 0.002002716064453125
▁new 0.060791015625
▁cases 0.0203857421875
▁diagn 0.054840087890625
osed 0.00012862682342529297
▁each 0.187255859375
▁year 5.1856040954589844e-05
. 0.037628173828125
▁While 2.73828125
▁traditional 3.166015625
▁treat 1.2763671875
ments 3.6954879760742188e-06
▁such 0.53076171875
▁as 9.78708267211914e-05
▁chem 1.00390625
other 0.00020015239715576172
apy 1.1920928955078125e-05
▁and 0.08038330078125
▁radiation 0.91357421875
▁ther 0.7060546875
apy 0.0002574920654296875
▁have 0.6767578125
▁improved 1.3349609375
▁surv 0.259521484375
ival 0.00016629695892333984
▁rates 0.0009946823120117188
, 0.2000732421875
▁they 0.69482421875
▁are 2.55078125
▁often 0.544921875
▁associated 0.180908203125
▁with 3.421306610107422e-05
▁significant 0.46826171875
▁side 0.00537109375
▁effects 0.00033402442932128906
. 1.0009765625
<0x0A> 0.400390625
The 0.70458984375
▁potential 1.7685546875
▁for 2.962890625
▁a 1.19921875
▁top 0.351806640625
ical 0.018463134765625
▁gel 0.47216796875
- 0.032470703125
based 0.0002961158752441406
▁treatment 0.048553466796875
▁like 1.89453125
▁Mar 0.0004432201385498047
im 0.000701904296875
ast 9.131431579589844e-05
at 8.928775787353516e-05
▁to 0.4130859375
▁offer 3.20703125
▁a 0.76904296875
▁more 0.84423828125
▁target 0.3037109375
ed 4.0531158447265625e-05
▁and 0.1539306640625
▁less 0.258056640625
▁invas 0.1248779296875
ive 2.0265579223632812e-06
▁treatment 3.12890625
▁option 0.10321044921875
▁is 0.96728515625
▁a 1.53125
▁significant 0.57373046875
▁development 0.76220703125
▁in 0.208740234375
▁the 0.03936767578125
▁fight 0.55810546875
▁against 8.726119995117188e-05
▁breast 0.04351806640625
▁cancer 0.0002880096435546875
. 0.015625
<0x0A> 0.5166015625
The 1.474609375
▁review 1.7470703125
▁of 0.07757568359375
▁Mar 0.0299224853515625
im 0.0009174346923828125
ast 0.00010251998901367188
at 0.0001583099365234375
▁at 0.12457275390625
▁the 0.07318115234375
▁ES 0.2420654296875
MO 3.0875205993652344e-05
▁conference 0.003337860107421875
▁will 2.0546875
▁provide 0.7958984375
▁an 0.7060546875
▁opportunity 0.5537109375
▁for 0.24853515625
▁health 1.921875
care 0.002300262451171875
▁profession 0.0269012451171875
als 2.384185791015625e-07
▁to 0.53369140625
▁consider 6.78125
▁the 0.26171875
▁potential 0.351806640625
▁benefits 1.7177734375
▁of 0.07373046875
▁the 0.70068359375
▁treatment 0.08673095703125
▁and 0.93701171875
▁to 2.19921875
▁discuss 0.7939453125
▁the 1.041015625
▁next 1.2421875
▁steps 0.003971099853515625
▁in 0.3203125
▁its 0.60595703125
▁development 0.175537109375
. 0.262939453125
▁With 3.599609375
▁the 1.0947265625
▁prospect 5.29296875
▁of 0.0088348388671875
▁impro 1.6630859375
ving 7.271766662597656e-06
▁surv 0.392822265625
ival 0.0002205371856689453
▁rates 0.005397796630859375
▁for 2.630859375
▁breast 0.38525390625
▁cancer 5.4836273193359375e-05
▁patients 0.00043010711669921875
, 0.2286376953125
▁the 0.6552734375
▁potential 3.1328125
▁of 0.82080078125
▁Mar 0.0792236328125
im 0.001377105712890625
ast 3.62396240234375e-05
at 0.00010585784912109375
▁is 0.36181640625
▁a 1.923828125
▁be 8.1953125
acon 0.0013360977172851562
▁of 0.0034847259521484375
▁hope 0.0029964447021484375
▁for 0.18603515625
▁millions 2.138671875
▁of 0.12200927734375
▁women 0.69091796875
▁around 0.348388671875
▁the 0.00010824203491210938
▁world 0.0118255615234375
. 0.126220703125
